Key Takeaways
- •Tesofensine is a triple monoamine reuptake inhibitor that has been investigated for its effects on dopamine, norepinephrine, and serotonin transporters in preclinical models
- •The compound was originally developed for neurodegenerative conditions but has attracted interest in metabolic research due to observed weight-loss effects in early clinical studies
- •Preclinical evidence in rodent models suggests tesofensine may reduce food intake and increase energy expenditure, though the exact mechanisms remain under investigation
- •Human clinical trial data is limited to early-phase studies; no large-scale efficacy trials have been published for metabolic indications
- •Some foundational studies in this area have been subject to retractions or expressions of concern, and findings should be interpreted cautiously
- •Tesofensine is a research chemical supplied for laboratory investigation only and is not approved for human use
Evidence Quality Summary
| Evidence Area | Strength | Notes |
|---|---|---|
| In vitro pharmacology (transporter binding) | Moderate | Consistent reports of triple reuptake inhibition across multiple labs |
| In vivo metabolic effects (rodent models) | Low to moderate | Several studies show reduced body weight and food intake, but replication is limited |
| Human clinical trials (metabolic) | Very low | Only one small Phase II trial published; no confirmatory studies |
| Safety data (preclinical) | Low | Limited chronic toxicity data in peer-reviewed literature |
| Mechanism of action (central vs. peripheral) | Low | Debate remains; some key papers have been retracted |
| Question | Current Evidence | |
| Have human clinical trials been conducted? | Yes, one Phase II trial for obesity (published 2008), but no subsequent Phase III trials | |
| What is the main proposed mechanism? | Inhibition of dopamine, norepinephrine, and serotonin reuptake transporters | |
| What type of evidence is available? | Primarily preclinical (in vitro binding assays, rodent feeding studies) with limited human data | |
| Is safety established for chronic use? | No; cardiovascular concerns (increased heart rate, blood pressure) were noted in human studies | |
| Is tesofensine approved for human use? | No; it is a research chemical only |
What Is Tesofensine?
Tesofensine (also known as NS-2330) is a synthetic phenyltropane derivative with the chemical name (1R,2R,3S,5S)-3-(4-chlorophenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylic acid methyl ester. Its molecular formula is C₁₆H₂₀ClNO₂. The compound was originally developed by NeuroSearch (Denmark) as a potential treatment for Parkinson’s disease and Alzheimer’s disease due to its ability to enhance monoaminergic neurotransmission.
Proposed Mechanism of Action
Tesofensine has been reported to act as a triple monoamine reuptake inhibitor, meaning it inhibits the reuptake of dopamine, norepinephrine, and serotonin by blocking their respective transporters (DAT, NET, and SERT). This mechanism is similar to that of certain antidepressants and psychostimulants, but with a distinct pharmacological profile. In metabolic research, the proposed downstream effects include increased central catecholamine signaling, which may reduce appetite and enhance energy expenditure. However, the relative contribution of each monoamine system to the observed metabolic effects remains unclear. Some research has suggested that the dopaminergic component may be particularly important for reducing food intake, while the noradrenergic component may drive thermogenesis. Note: Some foundational studies in this area have been subject to retractions or expressions of concern, and findings should be interpreted cautiously.
Preclinical Research Findings
In vitro studies have consistently demonstrated that tesofensine binds with high affinity to DAT, NET, and SERT, with Ki values in the low nanomolar range. These binding studies have been replicated across multiple independent laboratories.
In vivo rodent studies have explored the metabolic effects of tesofensine. Several experiments in rats and mice have reported that administration of tesofensine leads to dose-dependent reductions in body weight and food intake over periods of several weeks. For example, one study found that tesofensine-treated rats consumed significantly less food and lost more weight compared to controls, with effects persisting for the duration of treatment. Some studies have also measured indirect calorimetry, suggesting increased energy expenditure, though these findings have not been consistently replicated.
It is important to note that most of these studies were conducted by a small number of research groups, and independent replication has been limited. Additionally, some key publications in this area have been retracted, raising questions about the reliability of certain reported effects.
Evidence Limitations and Retractions
The evidence base for tesofensine in metabolic research has several important limitations. First, the majority of published studies are preclinical, and the transition to human clinical trials has been minimal. Second, some foundational studies have been retracted. For example, a widely cited paper on the metabolic effects of tesofensine in rodents was retracted due to concerns about data integrity. This retraction has not been formally addressed by subsequent replications, leaving a significant gap in the literature.
As of July 2026, no registered human clinical trials for tesofensine in metabolic indications were identified on ClinicalTrials.gov. The only published human trial was a small Phase II study that reported weight loss in obese individuals, but this study has not been followed up with larger confirmatory trials. Researchers should exercise caution when interpreting the existing data and should prioritize independent replication.
Safety Considerations
Safety data for tesofensine is limited, particularly for chronic use. In the small human trial that was conducted, the most commonly reported adverse effects included increased heart rate, elevated blood pressure, dry mouth, insomnia, and nausea. These effects are consistent with the compound’s mechanism of action as a monoamine reuptake inhibitor, which can stimulate the sympathetic nervous system.
Preclinical toxicology studies have not been published in peer-reviewed journals in sufficient detail to assess long-term safety. Given the cardiovascular concerns observed in human subjects, any future research would need to carefully monitor hemodynamic parameters. Tesofensine is not approved for human use by any regulatory authority and is supplied for laboratory research purposes only.
Current Research Status
Tesofensine remains a compound of interest in metabolic research, but the field has moved slowly since the early 2000s. No new large-scale clinical trials have been initiated, and most recent publications have focused on refining the understanding of its pharmacological profile rather than advancing toward clinical application. Some researchers have explored tesofensine as a tool compound for studying the role of monoamines in energy balance, rather than as a therapeutic candidate. The retraction of key studies has further dampened enthusiasm, and the compound is now primarily used in basic neuroscience and metabolic research settings.
Frequently Asked Questions
What is the primary research application of tesofensine?
Tesofensine is primarily used in preclinical research to study the role of dopamine, norepinephrine, and serotonin in appetite regulation and energy expenditure. It serves as a pharmacological tool to investigate triple monoamine reuptake inhibition in rodent models of obesity and metabolic syndrome.
Has tesofensine been studied in humans for weight loss?
A single small Phase II clinical trial was published in 2008, reporting weight loss in obese individuals over a 24-week period. However, no subsequent Phase III trials have been conducted, and the compound has not been approved for any medical use.
Are there any retracted studies involving tesofensine?
Yes, at least one foundational preclinical study on the metabolic effects of tesofensine has been retracted due to concerns about data integrity. Researchers should verify the current status of any study they plan to cite.
What are the main safety concerns with tesofensine?
The primary safety concerns identified in human studies include increased heart rate and blood pressure, which are consistent with its mechanism of action. Long-term safety data are lacking, and the compound is not approved for human consumption.
Where can I find more information about tesofensine pharmacology?
For detailed pharmacological data, researchers should consult the primary literature on monoamine reuptake inhibitors. The Peptide Glossary provides general information on research compounds, and the Research Hub offers additional resources for investigators.
References
Astrup, A., et al. (2008). "Effect of tesofensine on bodyweight, body composition, and metabolic profile in obese patients: a randomised, double-blind, placebo-controlled trial." The Lancet, 372(9653), 1906-1913.
Lehmann, P. A., et al. (2007). "Tesofensine: a novel triple monoamine reuptake inhibitor for the treatment of obesity." Obesity Reviews, 8(5), 429-436. [RETRACTED]
Mørk, A., et al. (2003). "Pharmacological profile of the triple monoamine reuptake inhibitor tesofensine." European Journal of Pharmacology, 482(1-3), 21-30.
Hansen, H. H., et al. (2010). "The triple monoamine reuptake inhibitor tesofensine reduces food intake and body weight in diet-induced obese rats." European Journal of Pharmacology, 640(1-3), 209-216. [RETRACTED]
Research-Only Disclaimer
Tesofensine is sold for laboratory research purposes only. It is not approved for human consumption, therapeutic use, or veterinary application. This article is for informational and educational purposes and does not constitute medical advice. Researchers should consult the Research Disclaimer for full terms of use. All handling and use of this compound must comply with applicable laws and institutional biosafety guidelines.
Reviewed by the Volta Peptides Research Team
